Overview

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Status:
Completed
Trial end date:
2009-01-07
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. 3-AP may help gemcitabine kill more tumor cells by making them more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving 3-AP together with gemcitabine works in treating patients with recurrent, unresectable, or metastatic pancreatic cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University Health Network, Toronto
Collaborator:
National Cancer Institute (NCI)
Treatments:
Gemcitabine